Hörmann H, Jelinić V, Richter H
Max-Planck-Institut für Biochemie, Martinsried bei München, Germany.
Blood Coagul Fibrinolysis. 1990 Oct;1(4-5):547-9. doi: 10.1097/00001721-199010000-00036.
Centrifuged human platelets bound soluble 125I-labelled fibrin, mediated by a plasma factor. Binding was inhibited by D-phenylalanyl-L-prolyl-L-arginyl- chloromethane (PPACK), which specifically blocks thrombin. As the binding-promoting principle was adsorbed to barium citrate, it was tentatively characterized as prothrombin, suggesting that it might be converted to thrombin at the cell surface. The peptide GRGDSP failed to inhibit binding, thus eliminating the glycoprotein IIb/IIIa complex as a receptor. Most likely, a thrombin - fibrin complex is recognized by a cell receptor, possibly protease-nexin I. In a platelet concentrate, the cells also internalized 125I-labelled fibrin, providing evidence that platelets are involved in the clearance of circulating fibrin - monomer complexes. Engulfment was again inhibited by PPACK or hirudin but not by an antibody against the glycoprotein IIb/IIIa complex.
通过血浆因子介导,离心后的人血小板可结合可溶性125I标记的纤维蛋白。D-苯丙氨酰-L-脯氨酰-L-精氨酰氯甲酮(PPACK)可抑制这种结合,它能特异性地阻断凝血酶。由于促进结合的物质被柠檬酸钡吸附,因此初步将其鉴定为凝血酶原,这表明它可能在细胞表面转化为凝血酶。肽GRGDSP未能抑制结合,因此排除了糖蛋白IIb/IIIa复合物作为受体的可能性。最有可能的是,凝血酶-纤维蛋白复合物被细胞受体识别,可能是蛋白酶连接素I。在浓缩血小板中,细胞也会内化125I标记的纤维蛋白,这表明血小板参与了循环纤维蛋白单体复合物的清除。PPACK或水蛭素再次抑制了吞噬作用,但抗糖蛋白IIb/IIIa复合物的抗体则没有。